Dose De-escalation in Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients on Concurrent Immunotherapy or Targeted Therapy: A Multicenter Experience
Authors:
- 25 June 2026
- journal article
- Published by Wolters Kluwer Health in Neurosurgery
Abstract
BACKGROUND AND OBJECTIVES: The American Society for Radiation Oncology guidelines for stereotactic radiosurgery dose suggestions for brain metastases provide excellent local control but at the expense of higher adverse radiation effects (ARE). This study provides evidence that lower single-fraction prescription doses for patients with melanoma metastases who are concurrently receiving immunotherapy or targeted therapy are equally effective and safe. METHODS: This retrospective, multicenter study included 335 patients with melanoma brain metastases who underwent stereotactic radiosurgery between 2009 and 2024. After covariate balancing, 137 patients with 590 metastases were included in the high dose (HD) group and 59 patients with 590 metastases in the reduced dose (RD) group. The RD limits were set at P = .5) and imaging follow-up (6 vs 6 months, P = .13) were comparable. Cumulative incidence of progressing metastases was significantly higher in the HD group compared with the RD group ( P < .001) overall, but lower prescription doses resulted in higher progression rates for metastases >2 cm ( P = .023). Higher prescription volumes and HD-group prescription doses were linked with local progression in multivariable analysis. Radiographic AREs were significantly more common in the HD group compared with the RD group overall ( P < .001) but similar for metastases >2 cm ( P = .7). Higher prescription volumes, HD-group prescription doses, and concurrent BRAF or other tyrosine kinase inhibitors were linked with an increased risk of radiographic ARE, whereas concurrent immunotherapy was associated with lower rates of radiographic ARE. CONCLUSION: This study provides evidence that treatment with prescription doses under the currently the American Society for Radiation Oncology-suggested doses for brain melanoma metastases <2 cm is safe, having at least equal local control rate and lower radiographic AREs. Reducing prescription dose for lesions between 2 and 3 cm does not seem to convey reduced ARE rates and could potentially increase local failure.Keywords
This publication has 27 references indexed in Scilit:
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024European Journal of Cancer, 2024
- Combined immunotherapy in melanoma patients with brain metastases: A multicenter international studyEuropean Journal of Cancer, 2024
- Stereotactic radiosurgery for melanoma brain metastases: dose-size response relationship in the era of immunotherapyJournal of Neuro-Oncology, 2021
- Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumabCancer Medicine, 2018
- Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic RadiationJAMA Oncology, 2018
- Practical recommendations for reportingFine‐Gray model analyses for competing risk dataStatistics in Medicine, 2017
- Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain MetastasesJAMA, 2016
- Single-Fraction Versus Multifraction (3 × 9 Gy) Stereotactic Radiosurgery for Large (>2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain NecrosisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain MetastasesJAMA Oncology, 2015
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995